Alto Neuroscience (NYSE:ANRO) Shares Gap Down – Here’s Why

Alto Neuroscience, Inc. (NYSE:ANRO)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $36.30, but opened at $35.00. Alto Neuroscience shares last traded at $35.37, with a volume of 22,504 shares.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Robert W. Baird dropped their target price on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, July 29th. Wall Street Zen raised shares of Alto Neuroscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Bank of America assumed coverage on Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Wolfe Research started coverage on Alto Neuroscience in a research note on Friday, May 22nd. They set an “outperform” rating for the company. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $37.25.

Alto Neuroscience Stock Down 2.0%

The company has a current ratio of 14.85, a quick ratio of 14.85 and a debt-to-equity ratio of 0.07. The business has a fifty day simple moving average of $28.53 and a two-hundred day simple moving average of $24.04. The company has a market cap of $1.40 billion, a PE ratio of -14.69 and a beta of 1.06.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.08. As a group, equities research analysts predict that Alto Neuroscience, Inc. will post -2.68 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

A number of hedge funds have recently bought and sold shares of ANRO. Quantinno Capital Management LP lifted its stake in Alto Neuroscience by 1.4% in the 1st quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock worth $811,000 after purchasing an additional 490 shares in the last quarter. Torren Management LLC purchased a new stake in shares of Alto Neuroscience in the fourth quarter valued at approximately $62,000. XTX Topco Ltd grew its position in shares of Alto Neuroscience by 32.2% in the fourth quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock valued at $371,000 after purchasing an additional 5,078 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Alto Neuroscience by 6.3% in the first quarter. Renaissance Technologies LLC now owns 103,499 shares of the company’s stock valued at $2,327,000 after purchasing an additional 6,100 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Alto Neuroscience by 26.1% in the first quarter. Dimensional Fund Advisors LP now owns 39,324 shares of the company’s stock valued at $884,000 after purchasing an additional 8,148 shares during the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.